<div id="readability-page-1">Valneva (NASDAQ:VALN) posted nine-month revenues that came in below market forecasts, though the vaccine developer reaffirmed its full-year guidance, sending its shares up 6% in Paris following the announcement. The company reported total nine-month revenue of €127 million and product sales of €119.4 million, missing the €132.3 million consensus estimate cited by Kepler Cheuvreux. Ixiaro, […]</div>

VALN

<p>Valneva 報告了九個月的收入為 1.27 億歐元，低於市場預測的 1.323 億歐元，但維持了全年指引。儘管未能達到收入預期，股價在巴黎上漲了 6%</p>

Valneva 收入未達預期但維持前景展望；股價上漲